BioWorld

Oct. 12, 2005

DNA Beats Consensus With Avastin, Herceptin Growth

Once again beating consensus estimates, Genentech Inc. reported a strong third quarter driven by better-than-expected sales of Avastin and Herceptin, two products that are increasingly being prescribed off-label. (BioWorld Today) Read More

CepTor Adding $20M To Test Myodur In Muscular Dystrophy

Antigenics Reports Positive Data From Oncophage Trial

VIRxSYS Series F Raises $31M To Boost HIV Drug

Praecis Continues Cost-Cutting Efforts, Sells Research Facility

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...